BiotechTube

KVD824 + Placebo to KVD824

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Angioedema, Hereditary, Types I and II

Conditions

Angioedema, Hereditary, Types I and II

Trial Timeline

Sep 27, 2021 → Oct 27, 2022

NCT ID
NCT05055258

About KVD824 + Placebo to KVD824

KVD824 + Placebo to KVD824 is a phase 2 stage product being developed by KalVista Pharmaceuticals for Angioedema, Hereditary, Types I and II. The current trial status is terminated. This product is registered under clinical trial identifier NCT05055258. Target conditions include Angioedema, Hereditary, Types I and II.

What happened to similar drugs?

3 of 20 similar drugs in Angioedema, Hereditary, Types I and II were approved

Approved (3) Terminated (1) Active (16)
✅Omalizumab + PlacebosNovartisApproved
✅Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injectionCSLApproved
✅GaradacimabCSLApproved
🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05055258Phase 2Terminated
NCT05178355Phase 1Completed

Competing Products

20 competing products in Angioedema, Hereditary, Types I and II

See all competitors
ProductCompanyStageHype Score
KVD900KalVista PharmaceuticalsPhase 2
29
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 1
23
KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
SebetralstatKalVista PharmaceuticalsPre-clinical
20
KVD900 + Placebo to KVD900KalVista PharmaceuticalsPhase 1
23
SebetralstatKalVista PharmaceuticalsPre-clinical
24
Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tabletKalVista PharmaceuticalsPhase 1
23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
34
KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
Omalizumab + PlacebosNovartisApproved
43
C1-esterase inhibitorCSLPhase 3
40
Low-volume C1-esterase inhibitor + Higher-volume C1-esterase inhibitor + Low-volume placebo + Higher-volume placeboCSLPhase 3
40
CSL312CSLPre-clinical
30
Berinert + CSL830CSLPhase 1
29
CSL312 + PlaceboCSLPhase 3
40
C1-Esterase InhibitorCSLPhase 3
40
C1 Esterase Inhibitor + PlaceboCSLPhase 2/3
38
CSL312CSLPhase 3
40
Berinert® (C1 Esterase Inhibitor)CSLPre-clinical
26